Dr. Jay Bhattacharya

Role status — October 2026: Bhattacharya remains NIH Director. He also served as acting CDC director from February to August 2026, until Erica Schwartz was confirmed to that post.

Jay Bhattacharya was born in 1968 in Kolkata, India, to a Bengali Hindu family, and later became a naturalized American citizen. He graduated with honors from Stanford University with both a bachelor’s and a master’s degree in economics in 1990, earning election to Phi Beta Kappa. He then simultaneously pursued a medical degree and a doctorate in economics at Stanford, completing both in the early 2000s.

Bhattacharya spent the bulk of his career as a professor of medicine, economics, and health research policy at Stanford University, where he led the Stanford Center on the Demography and Economics of Health and Aging. His research program focused on the economics of aging populations, the cost effectiveness of medical interventions, and the intersection of insurance design and health outcomes — a portfolio that put him inside both the medical and the economic communities studying American health policy.

He became a nationally visible figure during the COVID-19 pandemic as one of the three original signatories of the Great Barrington Declaration, released in October 2020. The declaration argued for “focused protection” of vulnerable populations rather than broad lockdown measures, and it put its signatories — Bhattacharya, Sunetra Gupta of Oxford, and Martin Kulldorff of Harvard — into sustained public conflict with the NIH leadership of the time. Internal NIH communications released in later records showed the depth of that institutional pushback.

His pandemic-era positions made him a defining figure in the academic-dissent coalition that later aligned with the MAHA agenda. He also became a plaintiff in Murthy v. Missouri, the Supreme Court case examining federal pressure on social-media platforms to moderate COVID-related speech.

On November 26, 2024, President-elect Trump named Bhattacharya as his nominee to direct the National Institutes of Health. The Senate confirmed him on March 25, 2025, by a party-line vote of 53 to 47. He left his Stanford faculty position to become emeritus professor so he could take up the NIH role, making him the first Indian-American to lead the agency.

As NIH Director, Bhattacharya oversees the world’s largest public biomedical-research funder, with a portfolio spanning twenty-seven institutes and centers. Publicly stated priorities include research-integrity reforms, broader review of the peer-review and grant-funding process, open data and replication standards, and restructuring intramural research priorities around chronic-disease burden.

On February 18, 2026, Bhattacharya was concurrently appointed Acting Director of the Centers for Disease Control and Prevention, making him one of a small number of officials in HHS history to lead NIH and CDC at the same time. That dual role puts him at the center of any coordinated research-and-public-health action coming from the MAHA policy agenda.

Current battles involve navigating the NIH workforce and grantee universe after a decade of pandemic-era tension, absorbing the political heat for any major grant-program realignment, and managing the Acting-CDC dual role without dropping either portfolio. Open questions: how durable the CDC acting appointment is, whether a permanent CDC Director is nominated in 2026, and whether Bhattacharya’s open-science agenda survives contact with the intellectual-property and industry-partnership structure of existing NIH-funded research.